Recon: Lilly Buys Immunotherapy Company for $1.6B – Regulatory Focus
Regulatory Focus |
Recon: Lilly Buys Immunotherapy Company for $1.6B
Regulatory Focus Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion (WSJ) (Bloomberg) (Endpoints) (STAT-$) (Fierce) (Reuters); Proposal to Curb Drug Prices Would Hand More Competition to Insurers (WSJ) (Fierce) (The Hill); Setback to Roche hopes … |
